An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.

The pharmaceutical industry has seen a tremendous surge in the development of weight loss drugs, particularly GLP-1 receptor ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...